Navigation Links
Arobella Medical CEO is Issued U.S. Patent for Ultrasound Wound Therapy Technology
Date:10/9/2008

Patent will protect next generation of Qoustic Wound Therapy System(R)

MINNEAPOLIS, Oct. 9 /PRNewswire/ -- Arobella Medical, LLC, a leader in advanced ultrasonic wound care devices, today announced that its Co-founder, President and CEO Eliaz Babaev, Ph.D., has been issued a U.S. patent that covers technology employed in the next generation of the company's Qoustic Wound Therapy System(R).

The Qoustic Wound Therapy System, which offers a safe, cost-effective alternative to painful sharps debridement and other surgical modalities, is emerging as the gold standard for wound care. Light guidance contact produces a dual delivery of low-frequency ultrasound energy directly on the wound bed. This process gently, thoroughly and efficiently debrides the wound and provides stable cavitation to remove dead or diseased tissue, harmful bacteria and biofilm. Ultrasonic treatment also expedites healing by preserving healthy tissue and protecting granulation tissue, improving circulation through vasodilation and angiogenesis, and preparing the wound bed for more effective use of downstream therapies such as grafts and flaps.

"This patent, which is the first of many that are currently pending, will help protect the next generation of this product that is poised to become the latest breakthrough in wound care today," said Babaev.

The first generation of the Qoustic Wound Therapy System family was launched in February 2008.

About Arobella Medical, LLC

Arobella Medical, LLC is a Minneapolis-based medical device company specializing in low-frequency ultrasound for wound care and other wound management therapies. Arobella Medical is positioned to become a leader in advanced ultrasound wound care technologies and devices. Arobella Medical Co-founder and CEO Eliaz Babaev has more than 40 years of experience developing, designing and commercializing medical devices that use ultrasound, with over 40 patents worldwide. He holds a Ph.D. degree from the Moscow Bauman School, a Doctor of Science degree from the Latvia Academy of Science, and a Doctor of Science degree from the Russian State Supreme Certification Committee, all in biomedical ultrasound. For more information, go to http://www.arobella.com


'/>"/>
SOURCE Arobella Medical, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM)
2. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
3. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
4. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
5. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
6. BioMS Medical announces its intention to renew a normal course issuer bid
7. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Globus Medical Announces Record 2nd Quarter 2007 Results
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
Breaking Biology News(10 mins):